JP2025527694A - Ｉｌ２変異体及びそれを含むタンパク質複合体 - Google Patents

Ｉｌ２変異体及びそれを含むタンパク質複合体

Info

Publication number
JP2025527694A
JP2025527694A JP2025511613A JP2025511613A JP2025527694A JP 2025527694 A JP2025527694 A JP 2025527694A JP 2025511613 A JP2025511613 A JP 2025511613A JP 2025511613 A JP2025511613 A JP 2025511613A JP 2025527694 A JP2025527694 A JP 2025527694A
Authority
JP
Japan
Prior art keywords
antibody
protein
protein complex
constant region
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025511613A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025527694A5 (enExample
Inventor
パン，ヒョジュ
チョン，ヨンジュン
チョン，ソンヨプ
パク，ヨンジン
カン，ソクチャン
パク，ボム
パク，サンヒョン
チョ，サンジュン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mustbio Co Ltd
Original Assignee
Mustbio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mustbio Co Ltd filed Critical Mustbio Co Ltd
Publication of JP2025527694A publication Critical patent/JP2025527694A/ja
Publication of JP2025527694A5 publication Critical patent/JP2025527694A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
JP2025511613A 2022-08-23 2023-08-21 Ｉｌ２変異体及びそれを含むタンパク質複合体 Pending JP2025527694A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20220105643 2022-08-23
KR10-2022-0105643 2022-08-23
KR20230057361 2023-05-02
KR10-2023-0057361 2023-05-02
PCT/KR2023/012348 WO2024043643A1 (ko) 2022-08-23 2023-08-21 Il2 변이체 및 이를 포함하는 단백질 복합체

Publications (2)

Publication Number Publication Date
JP2025527694A true JP2025527694A (ja) 2025-08-22
JP2025527694A5 JP2025527694A5 (enExample) 2025-09-19

Family

ID=90013668

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025511613A Pending JP2025527694A (ja) 2022-08-23 2023-08-21 Ｉｌ２変異体及びそれを含むタンパク質複合体

Country Status (6)

Country Link
EP (1) EP4578871A4 (enExample)
JP (1) JP2025527694A (enExample)
KR (1) KR102655850B1 (enExample)
CN (1) CN119790064A (enExample)
AU (1) AU2023330441A1 (enExample)
WO (1) WO2024043643A1 (enExample)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528728A (ja) * 2004-03-05 2007-10-18 カイロン コーポレーション 改善されたインターロイキン−２ムテイン
JP2015522525A (ja) * 2012-05-10 2015-08-06 ザイムワークス，インコーポレイテッド Ｆｃドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物
JP2019511905A (ja) * 2016-02-05 2019-05-09 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 標的サイトカインデリバリーのための組成物および方法
JP2019535269A (ja) * 2016-11-15 2019-12-12 セントロ ド インムノロジア モレキュラー インターロイキン２及びそれに由来するタンパク質の分泌レベルを増大させる方法。
JP2019535650A (ja) * 2016-09-29 2019-12-12 ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドＢｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ヘテロダイマー免疫グロブリン構造体及びその製造方法
JP2020033362A (ja) * 2014-08-29 2020-03-05 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 腫瘍を標的としたｉｌ−２バリアント免疫サイトカインとヒトｐｄ−ｌ１に対する抗体との併用療法
JP2020515275A (ja) * 2017-04-03 2020-05-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗ｐｄ−１抗体と突然変異ｉｌ−２とまたはｉｌ−１５とのイムノコンジュゲート
WO2021201615A1 (ko) * 2020-03-31 2021-10-07 한미약품 주식회사 신규한 면역 활성 인터루킨 2 아날로그

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009061853A2 (en) * 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
US10858428B2 (en) * 2016-09-28 2020-12-08 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
JP7765181B2 (ja) * 2017-12-19 2025-11-06 ゼンコア インコーポレイテッド 改変されたｉｌ－２ ｆｃ融合タンパク質
CA3098930A1 (en) * 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
AU2020372429A1 (en) 2019-10-25 2022-04-28 Audentes Therapeutics, Inc. Compositions and methods for treating glycogen storage disorders
KR102559355B1 (ko) * 2020-01-31 2023-07-25 주식회사 제넥신 항-taa 항체, 항-pd-l1 항체 및 il-2를 포함하는 융합단백질 및 이의 용도
US20230295394A1 (en) 2020-08-26 2023-09-21 Reventas Limited Improvements In Or Relating To Plastic Recycling

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528728A (ja) * 2004-03-05 2007-10-18 カイロン コーポレーション 改善されたインターロイキン−２ムテイン
JP2015522525A (ja) * 2012-05-10 2015-08-06 ザイムワークス，インコーポレイテッド Ｆｃドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物
JP2020033362A (ja) * 2014-08-29 2020-03-05 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 腫瘍を標的としたｉｌ−２バリアント免疫サイトカインとヒトｐｄ−ｌ１に対する抗体との併用療法
JP2019511905A (ja) * 2016-02-05 2019-05-09 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ 標的サイトカインデリバリーのための組成物および方法
JP2019535650A (ja) * 2016-09-29 2019-12-12 ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドＢｅｉｊｉｎｇ Ｈａｎｍｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． ヘテロダイマー免疫グロブリン構造体及びその製造方法
JP2019535269A (ja) * 2016-11-15 2019-12-12 セントロ ド インムノロジア モレキュラー インターロイキン２及びそれに由来するタンパク質の分泌レベルを増大させる方法。
JP2020515275A (ja) * 2017-04-03 2020-05-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗ｐｄ−１抗体と突然変異ｉｌ−２とまたはｉｌ−１５とのイムノコンジュゲート
WO2021201615A1 (ko) * 2020-03-31 2021-10-07 한미약품 주식회사 신규한 면역 활성 인터루킨 2 아날로그

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. IMMUNOTHER., vol. 32(9), JPN6026009036, 2009, pages 887 - 894, ISSN: 0005814007 *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 10, JPN6026009035, 2000, pages 6790 - 6797, ISSN: 0005814006 *

Also Published As

Publication number Publication date
EP4578871A4 (en) 2026-07-08
AU2023330441A1 (en) 2025-02-20
KR102655850B1 (ko) 2024-04-11
EP4578871A1 (en) 2025-07-02
KR20240028310A (ko) 2024-03-05
CN119790064A (zh) 2025-04-08
WO2024043643A1 (ko) 2024-02-29

Similar Documents

Publication Publication Date Title
JP7118117B2 (ja) 抗体－薬物コンジュゲートの選択的製造方法
AU2018393424B2 (en) Triabody, preparation method and use thereof
CA3195675A1 (en) Anti-4-1bb-anti-pd-l1 bispecific antibody, and pharmaceutical composition and use thereof
US20250340631A1 (en) Cldn18.2-targeting antibody, bispecific antibody and use thereof
JP2022538375A (ja) Ｐｄ－１と結合する抗体
AU2017436815A1 (en) Anti-glyco-muc1 antibodies and their uses
CN115038720A (zh) 抗gprc5d单克隆抗体及其用途
WO2024193705A1 (en) Tnf superfamily member immunocytokine and uses thereof
JP2025098135A (ja) Ｐｄ－１ポリペプチド変異体
US12122845B2 (en) Anti-HER2/anti-4-1BB bispecific antibodies and uses thereof
JP2023530720A (ja) Ｌｅｗｉｓ Ｙに対するヒト化抗体
CN116496404A (zh) 靶向cd47和pd-l1的双特异性抗体及其应用
WO2023143547A1 (zh) 抗cd28抗体及其应用
KR20140025836A (ko) 항 ＨＥＲ2/Ｎｅｕ 단일클론항체와 ＩＬ-7가 연결된 융합 단일클론 항체 및 이를 포함하는 암 치료용 조성물
JP2024123082A (ja) 二重特異抗体またはその抗原結合断片、及びそれを製造する方法
KR102655850B1 (ko) Il2 변이체 및 이를 포함하는 단백질 복합체
CN119421898A (zh) 抗lypd3抗体
EP4682170A1 (en) Novel cd3-binding antibody and multispecific antibody comprising same
RU2818312C9 (ru) Биспецифическое антитело или его антигенсвязывающий фрагмент и способ их получения
RU2818312C1 (ru) Биспецифическое антитело или его антигенсвязывающий фрагмент и способ их получения
KR20130057959A (ko) 항 ｈｅｒ2 단일클론항체와 ｉｌ-2를 포함하는 융합 단일클론 항체 및 이를 포함하는 암치료용 조성물

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250910

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260608

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260714

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260806